Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

SLU-PP-332 research overview

SLU-PP-332 is an experimental small molecule—not a peptide—developed as an agonist at estrogen-related receptors (ERRs), with greatest reported potency at ERR-alpha.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is SLU-PP-332?

Discovery and follow-up work used receptor assays, cultured cells, and mouse exercise or metabolic-disease models.

Research category

Metabolic & energy research

Study models represented

Receptor assays, cultured cells, and mouse models

Names in the literature

Pan-ERR agonist; ERR-alpha agonist tool compound

Primary boundary

No cited human trial establishes safety, efficacy, or an exercise substitute.

What does the selected evidence support?

The research is preclinical. Descriptions such as “exercise mimetic” summarize selected model behavior and should not be treated as evidence of equivalent effects in humans.

Primary sources

1. Billon et al., ACS Chemical Biology (2023) — Discovery pharmacology and mouse exercise-endurance experiments. DOI: 10.1021/acschembio.2c00720
2. Huang et al., Journal of Pharmacology and Experimental Therapeutics (2023) — Preclinical metabolic-syndrome experiments in mouse models. DOI: 10.1124/jpet.123.001733

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review SLU-PP-332 product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.